Gilva Therapeutics, INC.
No. 18, Siyuan St., Zhongzheng Dist., Taipei City 100047 ,
Taiwan (R.O.C.) (Room 909 of Complex for Research Excellence)
Registration No.：89114272
TEL：+886 2 33661914
FAX：+886 2 23652804
INTRODUCTION
Gilva is a biopharmaceutical company focused on the development of small molecule drugs for unmet medical needs, especially in rare diseases.
Gilva has a robust drug discovery and development platform. This platform effectively optimizes the efficacy, druggability or safety of drugs based on the structure-activity relationship (SAR). Gilva also has a team with extensive experience in drug development, which can improve the efficiency of drug discovery and reduce development risks.
PIPELINE
GV-100
GV-100 is an oral selective HDAC6 inhibitor. HDAC6 interacts with various substrate proteins, regulating numerous cell physiological or pathological mechanisms. It exerts functions such as anti-inflammatory, anti-fibrotic, and cytoprotective effects by modulating post-translational modifications of crucial proteins within cells. HDAC6 is also overexpressed in ADPKD, fibrotic diseases, neurodegenerative disorders, and cancers, highlighting its significant role in various diseases.
NEWS
Gilva Therapeutics Collaborates with National Taiwan University to Publish First-Generation HDAC6 Inhibitors for ADPKD in the Journal of Medicinal Chemistry
2026/1/12 Forward Asset Management Inc. has resigned as a Board director of Gilva Therapeutics INC., and one replacement director will be appointed to fill the resulting vacancy.
2025/4/30 Annual Meeting of Shareholders